NRx Pharmaceuticals subsidiary HOPE signs definitive agreement to acquire Kadima Neuropsychiatry Institute

NRX Pharmaceuticals, Inc.

Kadima is a profitable interventional psychiatry clinic in La Jolla, CA, expected to serve as clinical model for HOPE network.
Dr. David Feifel, Kadima founder, to join HOPE as Chief Medical Innovation Officer upon closing.
Acquisition expected to be accretive to revenue and EBITDA for NRx and HOPE.
Closing subject to customary conditions and finalization of financing; further details to follow.
Kadima is a leading investigative site for CNS and psychedelic research, including ketamine and TMS.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.